Altimmune, Inc. cash flow to debt ratio of -189.24% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Altimmune, Inc.'s free cash flow has increased -15.41% from $-79.85M last year to $-67.55M, signaling increasing performance

Altimmune, Inc.'s debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Altimmune, Inc.'s debt has increased relative to shareholder equity from 0.01 last year to 0.13 today, signaling weakened financials

Altimmune, Inc. has negative EBITDA, making leverage ratio unreliable

Altimmune, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Altimmune, Inc.'s profit margin has increased (-46.77%) in the last year from -475.30K% to -253.00K%, signaling increasing performance

Altimmune, Inc.'s short-term assets of $278.19M exceed its short-term liabilities of $15.00M

Altimmune, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Altimmune, Inc.'s return on equity of -42.57%, is lower than 15.00%, indicating bad performance

Altimmune, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Altimmune, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Altimmune, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Altimmune, Inc. has negative free cash flow, indicating cash burn

Altimmune, Inc.'s yearly earnings has increased -7.33% since last year from $-95.06M to $-88.09M, signaling increasing performance

Altimmune, Inc.'s yearly revenue has increased 105.00% since last year from $20.00K to $41.00K, signaling increasing performance

ROIC -29.86% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Altimmune, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Altimmune, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Altimmune, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Altimmune, Inc. has insufficient data to evaluate this check.

Altimmune, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Altimmune, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Altimmune, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Altimmune, Inc. is overvalued relative to its fair value price of -3.95 based on Earnings Fair Value model

Altimmune, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Altimmune, Inc. has a price-to-book ratio of 1.28x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Altimmune, Inc. has a price-to-sales ratio of 9.77Kx, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue